Evidence map›Paper›PMID 38893194›Full record

ArticleCancers2024

Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms.

Lucienne Bogun, Annemarie Koch, Bo Scherer, Ulrich Germing, Roland Fenk, Uwe Maus, Felix Bormann, Karl Köhrer, Patrick Petzsch, Thorsten Wachtmeister and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucienne BogunDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Annemarie KochDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Bo SchererDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Uwe MausDepartment of Orthopedic Surgery and Traumatology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Felix BormannBioinformatics.Expert UG, 12305 Berlin, Germany.ORCID 0000-0002-5919-3375
Karl KöhrerBiological and Medical Research Center (BMFZ), Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Düsseldorf, Germany.ORCID 0000-0003-3644-2022
Patrick PetzschBiological and Medical Research Center (BMFZ), Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Düsseldorf, Germany.ORCID 0000-0002-8355-5524
Thorsten WachtmeisterBiological and Medical Research Center (BMFZ), Medical Faculty, Heinrich-Heine-University, Universitätsstraße 1, 40225 Düsseldorf, Germany.ORCID 0000-0002-6760-2458
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Sascha DietrichDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Rainer HaasDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.ORCID 0000-0002-3652-6595
Thomas SchroederDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Stefanie GeyhDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.
Paul JägerDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, 40225 Duesseldorf, Germany.ORCID 0000-0001-9250-2064

Funding

DFG DFG 417677437/GRK2578
6 · The paper itself

Abstract

Myeloid and lymphoid neoplasms share the characteristics of potential bone marrow infiltration as a primary or secondary effect, which readily leads to hematopoietic insufficiency. The mechanisms by which clonal malignant cells inhibit normal hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM) have not been unraveled so far. Given the pivotal role of mesenchymal stromal cells (MSCs) in the regulation of hematopoiesis in the BM niche it is assumed that MSCs also play a relevant role in the pathogenesis of hematological neoplasms. We aimed to identify overlapping mechanisms in MSCs derived from myeloid and lymphoid neoplasms contributing to disease progression and suppression of HSPCs to develop interventions that target these mechanisms. MSCs derived from healthy donors (

Indexed as

ALLAMLbone marrow microenvironmenthematopoietic insufficiencylymphoid neoplasmsMDSMPNMSCmyeloid neoplasmsNHLosteogenesisRNA sequencing

Identifiers

PMID38893194
PMCPMC11171322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.